Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -72.42% is 49% below its 5-year average of -48.77%, near the low end of its 5-year range (-95.18%–-15.13%).
9.68% below its 12-month average of -66.03%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -17.01%.
RETURN ON ASSETS (ROA)
-72.42%
RETURN ON ASSETS (ROA) AVG TTM
-66.03%
RETURN ON ASSETS (ROA) AVG 3Y
-45.57%
RETURN ON ASSETS (ROA) AVG 5Y
-48.77%
RETURN ON ASSETS (ROA) AVG 10Y
N/A
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
-9.68%
CURRENT VS 3Y AVG
-58.92%
CURRENT VS 5Y AVG
-48.51%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-28.83%
median of 588 covered companies
CURRENT VS SECTOR MEDIAN
-151.20%
vs the sector median at left
Caribou Biosciences, Inc.
Market Cap
$116.54M
Return on Assets (ROA)
-72.42%
TTM Avg
-66.03%
3Y Avg
-45.57%
5Y Avg
-48.77%
Market Cap
$116.57M
Return on Assets (ROA)
-167.64%
TTM Avg
-183.95%
3Y Avg
-119.46%
5Y Avg
-95.34%
Market Cap
$116.83M
Return on Assets (ROA)
-53.26%
TTM Avg
-24.98%
3Y Avg
-43.10%
5Y Avg
-143.56%
Market Cap
$114.79M
Return on Assets (ROA)
-128.96%
TTM Avg
-127.49%
3Y Avg
-112.64%
5Y Avg
-129.28%
Market Cap
$114.62M
Return on Assets (ROA)
-19.30%
TTM Avg
-19.59%
3Y Avg
-15.38%
5Y Avg
-15.18%
Market Cap
$120.24M
Return on Assets (ROA)
-96.49%
TTM Avg
-109.25%
3Y Avg
-126.41%
5Y Avg
-190.40%
Market Cap
$112.52M
Return on Assets (ROA)
-134.18%
TTM Avg
-145.83%
3Y Avg
-164.39%
5Y Avg
-180.40%
Market Cap
$112.36M
Return on Assets (ROA)
-0.05%
TTM Avg
-38.03%
3Y Avg
-60.31%
5Y Avg
-59.32%
Market Cap
$121.25M
Return on Assets (ROA)
-1.70%
TTM Avg
-35.34%
3Y Avg
-51.03%
5Y Avg
-36.99%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Caribou Biosciences, Inc. (CRBU) | $116.54M | -72.42% | -66.03% | -45.57% | -48.77% |
| Insight Molecular Diagnostics Inc. (IMDX)vs › | $116.57M | -167.64% | -183.95% | -119.46% | -95.34% |
| LENZ Therapeutics, Inc. (LENZ)vs › | $116.83M | -53.26% | -24.98% | -43.10% | -143.56% |
| Genelux Corporation (GNLX)vs › | $114.79M | -128.96% | -127.49% | -112.64% | -129.28% |
| MaxCyte, Inc. (MXCT)vs › | $114.62M | -19.30% | -19.59% | -15.38% | -15.18% |
| TuHURA Biosciences, Inc. (HURA)vs › | $120.24M | -96.49% | -109.25% | -126.41% | -190.40% |
| Lucid Diagnostics Inc. (LUCD)vs › | $112.52M | -134.18% | -145.83% | -164.39% | -180.40% |
| Coya Therapeutics, Inc. (COYA)vs › | $112.36M | -0.05% | -38.03% | -60.31% | -59.32% |
| enGene Holdings Inc. (ENGN)vs › | $121.25M | -1.70% | -35.34% | -51.03% | -36.99% |
| Cumberland Pharmaceuticals Inc. (CPIX)vs › | $110.73M | -16.87% | -6.13% | -6.48% | -5.59% |
ROA
-72.4%
ROE
-105.4%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -84.47% |
| 2024-12-31 | -47.59% |
| 2023-12-31 | -23.62% |
| 2022-12-31 | -26.60% |
| 2021-12-31 | -15.13% |
| 2020-12-31 | -95.18% |
| 2019-12-31 | -37.83% |
